The Antoine Priore Files: France's State-Funded Plasma Therapy

In 1960s Bordeaux, an Italian-French radar operator named Antoine Priore built a plasma-tube device that reportedly produced complete remission of terminal cancer in hundreds of animal experiments. The work was funded by the French government, conducted at the University of Bordeaux in collaboration with CNRS researchers, supported by Prime Minister Jacques Chaban-Delmas himself, and published in peer-reviewed French journals from 1965 to 1974. Then in 1974, the program ended. This is the most rigorously documented — and least explainable — chapter in the 130-year electromedicine lineage.

The man and his apparatus

Antoine Priore (1912–1983) was born in Italy and emigrated to France, where he trained as a radar operator and electrical engineer during the Second World War. Radar was 1940s frontier technology — high-voltage circuits, microwave generators, vacuum tube electronics, magnetic field manipulation. Priore absorbed it all, and after the war he turned his expertise toward a question that had no commercial value but apparently obsessed him: what would happen if you exposed living tissue to a carefully composed mixture of electromagnetic, plasma, and microwave fields all at once?

The device Priore eventually built combined elements that no single electromagnetic medical instrument before or since has integrated in quite the same way:

Notice the architecture: a Tesla-coil-driven noble gas plasma at the center, surrounded by a strong static magnetic field, modulated by a microwave carrier, with two close-spaced HF oscillators producing a beat frequency. This is precisely the combinatorial principle Georges Lakhovsky proposed forty years earlier — multiple simultaneous frequencies — but with the addition of a magnetic substrate and microwave envelope.

The animal would be placed inside this composite field for typically twenty minutes per session. No surgery. No injection. No drug. No contact.

The animal studies

The clinical evidence Priore generated is what separates his case from every other chapter in this lineage. He did not produce anecdotes. He produced hundreds of controlled animal experiments at the University of Bordeaux, in collaboration with credentialed CNRS researchers and university physicians. The studies were published in Comptes Rendus de l'Académie des Sciences — the official journal of the French Academy of Sciences, one of the oldest peer-reviewed scientific publications in the world^[1] — between 1965 and 1974.

The reported results, in his published animal studies:

• Complete remission of terminal mammary tumors in rats injected with T8 lymphosarcoma cells
• Reversal of leukemia (lymphoid leukemia LL/2) in mice
• Cure of trypanosomiasis (African sleeping sickness, Trypanosoma equiperdum) in rabbits — a particularly notable result because trypanosomiasis is a parasitic infection, not a tumor
• Survival times in treated animals that were many multiples of survival times in matched controls

These were not pilot studies. The Bordeaux experiments involved hundreds of animals, blinded protocols where pathologists who did not know which animals were treated examined post-mortem tissue, and replication runs that were repeated across multiple years. The methodology was respectable by the standards of 1965-1974 experimental medicine.

"Les résultats obtenus par M. Priore sur les tumeurs T8 sont incontestables et reproductibles." / "The results obtained by Mr. Priore on T8 tumors are incontestable and reproducible."
— Robert Courrier, Permanent Secretary of the French Academy of Sciences, 1971

The state-funded chapter

Priore was not a marginal figure. By the late 1960s, French scientific and political establishment took his work seriously enough to fund it directly.

In 1970, the Mayor of Bordeaux laid the cornerstone for Priore's new laboratory^[2] — a public ceremony attended by university officials, CNRS researchers, and members of the National Assembly. The funding came from a combination of the French national research budget, the city of Bordeaux, and private industry partners. Jacques Chaban-Delmas, then Prime Minister of France under President Pompidou and a longtime mayor of Bordeaux, was a personal supporter of the project.

The Chaban-Delmas government allocated millions of francs to scale up Priore's device into a larger clinical-trial-ready apparatus. Construction of a much larger machine — capable of treating human-sized subjects — began in the early 1970s. The expectation was that successful animal trials would lead within a few years to controlled human studies under French Ministry of Health oversight.

This is what makes the Priore affair categorically different from the contested American chapter (Royal Rife, covered at the lineage page): Priore had institutional cover, government funding, named CNRS collaborators publishing in Comptes Rendus, and the personal backing of a sitting French Prime Minister. He was operating inside the French scientific mainstream, not outside it.

What happened in 1974

Two things changed in 1974, and both contributed to the program's collapse:

1. Political turnover

Pompidou died unexpectedly in April 1974. Valéry Giscard d'Estaing was elected President. Chaban-Delmas, who had been the obvious successor, was politically marginalized. The new government had no particular investment in Priore's project and quietly removed it from the priority list.

2. Mechanism opacity

Even his strongest scientific defenders could not explain how the device worked. Priore himself was a self-taught engineer, not a theoretical physicist. He could specify the apparatus's parameters precisely, but he could not derive from first principles why those specific parameters produced the effects he documented. The CNRS researchers who collaborated with him faced the same problem: the empirical results were repeatable, but the theoretical mechanism was not.

In an era when scientific funding was beginning to require strong theoretical grounding, this was fatal. The unrestricted funding dried up. Priore continued working privately until his death in 1983. His apparatus was eventually lost or dismantled. The large clinical-scale device was never completed.

What Priore means for the Tesla BioLights lineage

The S.E.A.D. System inherits the Priore apparatus's basic architecture more directly than any other device in the modern wellness market. Compare:

• Plasma tube driven by high-voltage — Priore: yes. S.E.A.D.: yes.
• Multiple simultaneous frequencies (broad-spectrum) — Priore: yes (the two HF oscillators + microwave + plasma broadband emission). S.E.A.D.: yes (Tesla coil-driven broadband field across visible + near-IR + RF).
• Non-contact treatment — Priore: yes. S.E.A.D.: yes.
• Treatment at radio/microwave frequencies (non-thermal) — Priore: yes. S.E.A.D.: yes.
• Honest acknowledgment that the mechanism is incompletely understood — Priore: forced into honesty by his lack of theoretical training. S.E.A.D.: chosen as a matter of principle.

The S.E.A.D. System does not claim Priore's clinical results. We do not have his apparatus. We have not run his protocols. We make no medical claims and we do not promise the kinds of tumor-remission outcomes Priore reported. What we do claim is the engineering lineage: this category of device — broadband electromagnetic plus plasma photonic emission, non-contact, non-thermal — has a serious historical precedent that was funded by a sovereign government and published in the journal of one of the world's oldest scientific academies.

That precedent deserves to be remembered. It also deserves the same scientific scrutiny the 2025 paper "Resonant Convergence: EM Interactions in Biological Systems"^[3] is finally beginning to apply to the broader category. We may be approaching the equipment and the funding environment to revisit Priore properly.

Tomorrow on the Journal

Day 9: Royal Rife, Honestly. The American chapter that gets all the cultural attention and deserves a much more careful examination than the internet usually gives it. Where Priore had French government backing and CNRS collaborators publishing in Comptes Rendus, Rife had a much more contested record — and Tesla BioLights' position on him is more cautious than enthusiastic. Tomorrow we explain why.

Where the Priore lineage reaches in this Journal

Priore's plasma-tube + magnetic-field + dual-frequency device is, conceptually, the closest historical precedent for what Tesla BioLights actually does. Day 14 (the inert pharmacology of noble gases) covers the modern pharmacology of the gases inside the plasma tubes. Day 13 (the 600–1100 nm optical window) covers the wavelengths the plasma emits. Day 12 (Mitochondria as Light Antennae) covers the cytochrome c oxidase target. Day 16 (the quantum floor of biology) covers the radical-pair mechanism by which Earth-strength magnetic fields can do real biological work — the physics underneath the Priore field component.

For the full 130-year lineage from Tesla through Priore, Popp, and Levin, see our lineage page. For the peer-reviewed scientific deep-dive across all twelve domains the S.E.A.D. System draws from, see the science page.